GSA Capital Partners LLP Acquires Shares of 15,658 Hologic, Inc. $HOLX

GSA Capital Partners LLP bought a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,658 shares of the medical equipment provider’s stock, valued at approximately $1,057,000.

Other large investors have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its position in Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after acquiring an additional 8,227,318 shares during the period. Invesco Ltd. increased its holdings in shares of Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after purchasing an additional 3,505,828 shares during the period. Norges Bank purchased a new stake in shares of Hologic during the second quarter worth approximately $180,055,000. Black Creek Investment Management Inc. lifted its holdings in shares of Hologic by 26.1% during the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock worth $262,453,000 after purchasing an additional 832,444 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Hologic in the 2nd quarter valued at $48,283,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a report on Friday, November 21st. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Morgan Stanley boosted their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and increased their price target for the company from $70.00 to $78.00 in a report on Thursday, October 23rd. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Price Performance

HOLX stock opened at $75.14 on Friday. The stock has a market capitalization of $16.77 billion, a price-to-earnings ratio of 31.31, a price-to-earnings-growth ratio of 2.24 and a beta of 0.72. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.36. The stock’s fifty day simple moving average is $74.91 and its 200-day simple moving average is $71.80.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.87 earnings per share. Equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.